Treatment Advancements in Newly Diagnosed and Relapsed/Refractory in Multiple Myeloma - Episode 13
Insights Into CAR T Therapy in Earlier vs Later Lines
Panelists discuss how the CARTITUDE-4 data support early use of ide-cel in triple class–exposed myeloma patients, emphasizing the importance of avoiding attrition by not delaying highly effective therapies.
Ide-cel in Earlier Lines and CAR-T Sequencing Challenges
The KarMMa-3 trial demonstrated that ide-cel significantly outperforms standard regimens even in earlier lines of therapy for triple-class-exposed patients. However, sequencing remains a major consideration due to attrition risks in heavily pretreated populations.
Earlier use of CAR T may offer better efficacy and safety by targeting patients before disease becomes too aggressive or refractory. These findings challenge the notion of reserving CAR T for late-line therapy and support its use in the third-line setting or sooner.
Timely access and effective patient counseling are key, as patients may otherwise miss the opportunity for a potentially transformative therapy. Earlier intervention with CAR T should be a shared decision informed by disease trajectory and patient health.
Related Content:
